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SUMMARY 
Patients with Alzheimer's disease (AD) and major depression have been shown to have overlapping 
clinical symptoms and biological markers, including decreased concentrations of cerebrospinal 
fluid (CSF) somatostatin-like immunoreactivity (SLI), which may be related to alterations in the 
hypothalamic-pituitary-adrenal axis activity. As in prior studies, we found that CSF SLI was 
significantly decreased in a group of AD patients (N = 49) and a group of elderly patients with 
major depression (N = 18), as compared with 13 age-matched controls (F[2, 77] = 12.9, p < .001). 
In the present study, CSF SLI and CSF corticotropin-releasing factor correlated significantly within 
the group of AD patients (r = 0.49, p < .0004) and almost attained significance in the depressed 
patients (r = 0.47, p < .07). CSF SLI correlated significantly with urinary free cortisol within each 
patient group (r = -0.51, p < .03). Clinical measures of dementia severity and depression did not 
consistently correlate with CSF SLI in either patient group. 
INTRODUCTION 
DEPRESSED MOOD HAS been increasingly recognized as an important symptom in Alzhei- 
mer's disease (AD) patients; from 17% to 87% are estimated to have significant depression 
at some time during the course of the disease (Fischer et al., 1990; Lazarus et al., 1987; 
Rovner et al., 1989). Biological markers of major depression such as nonsuppression on 
the dexamethasone suppression test (DST) and blunting of the thyroid-stimulating hor- 
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mone response to administered thyrotropin-releasing hormone may also occur in AD 
patients to about the same degree as in patients with major depression (Carroll, 1985; 
Greenwald et al., 1986; Loosen, 1985; Molchan et al., 1990, 1991b; Raskind et al., 1982; 
Skare et al., 1990). In addition, patients with AD and major depression have been 
consistently shown to have decreased concentrations ofcerebrospinal fluid (CSF) somato- 
statin-like immunoreactivity (SLI) (Agren & Lundqvist, 1984; Beal et al., 1986; Bissette 
et al., 1986; Davis et al., 1988; Molchan et al., 1991a; Oram et al., 1981; Rubinow, 1986; 
Soininen et al., 1984; Sunderland et al., 1987). In the brain, the highest concentrations 
of somatostatin occur in the hypothalamus and limbic system (Rubinow, 1986), areas 
thought to be involved in cognitive and affective functions. 
Interactions between somatostatin and the hypothalamic-pituitary-adrenal (HPA) 
axis have been examined in many preclinical and clinical studies (Doran et al., 1986; 
Kaye et al., 1988; Rubinow, 1986; Serby et al., 1986; Wolkowitz et al., 1987). Somatostatin 
has been shown to inhibit stimulated and stress-induced corticotropin-releasing factor 
(CRF) and corticotropin (ACTH) release (Brown et al., 1984; Heisler et al., 1982; Richard- 
son & Schronbrunn, 1981). A positive relationship has generally been found between 
CSF SLI and CSF CRF in normal control and some patient populations (Berrettini et 
al., 1987; Kaye et al., 1988; Rubinow et al., 1987). In patients with major depression 
(Rubinow, 1986) and dementia (Serby et al., 1986), CSF SLI has been shown to correlate 
inversely with postdexamethasone plasma cortisol concentrations. 
In this study, we sought to determine if there are similarities in relationships between 
CSF SLI, HPA measures, and measures of mood in AD patients and in patients with 
major depression because of the overlapping clinical symptoms and abnormal biological 
measures, including reduced CSF SLI levels, in these two illnesses. 
METHODS 
Subjects 
Forty-nine patients with AD (mean age -+ SD = 66.3 --+ 8.6 years; 23 women, 26 men) 
and 18 patients with major depression (64.6 __. 9.9 years; 12 women, 6 men) were included 
in the study. Thirteen normal controls (63.5 -_+ 10.0 years; 3 women, 10 men) were 
included for comparisons of CSF SLI and CRF. All patients were studied as inpatients 
at the National Institute of Mental Health (NIMH); normal controls were studied as 
outpatients. Primary degenerative dementia of the Alzheimer type (AD) and major depres- 
sion were diagnosed according to DSM-III-R criteria (American Psychiatric Association, 
1987) using semi-structured interviews, laboratory and brain imaging studies, and physical 
examinations. Clinical and demographic data for the patients are summarized in Table 
I. Some AD patients had significant depressive symptoms, and may have had a prior 
history of major depression. Patients with serious medical problems were excluded 
from the study. Those patients diagnosed with major depression had a prior history of 
depressive episodes (i.e., their depression was not late-onset), did not have significant 
cognitive impairment at the time of testing, and responded to treatment with either 
antidepressant medication or electroconvulsive therapy. Clinical and biological data were 
collected during a 3-week drug-free period. Patients diagnosed with major depression 
and normal controls were administered the Wechsler Memory Scale-Revised (Wechsler, 
1987) to ensure that their cognitive functioning was within the range of normal. Controls 
were also screened using a semi-structured interview, physical examination, and labora- 
tory tests; those with a personal or family history of any significant medical, cognitive, 
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TABLE I. DEMOGRAPHIC AND BEHAVIORAL DATA FOR ALZHEIMER'S DISEASE AND 
MAJOR DEPRESSSION PATIENTS (MEAN ----- SD)  
Alzheimer's (n = 49) Depressed (n = 18) 
Age (years) 
Gender 
Illness duration (years) 
Age of onset (years) 
Dementia Mood Assessment Scale-17 
Hamilton Depression Scale (17 item) 





Global Deterioration Scale 
Clinical Dementia Rating Scale 
66.3 -+ 8.6 64.6 +- 9.9 
23F, 26M 12F, 6M 
4.2 -+ 2.6 
62.1 - 8.9 
22.9 --- 10.1 
--  22.4 --- 7.1 
4.0 -+ 1.8 6.9 --- 2.1 
4.7 --- 1.6 6.6 --- 1.4 
1.8 -+ 1.3 2.1 - 2.2 
4.5 --+ 0.9 
1.6 -+ 0.6 
or psychiatric disorder were excluded. They were recruited from the community and 
paid for their participation. All subjects were free of centrally active drugs for at least 
3 weeks before the study. The study was approved by the NIMH protocol review 
committee after review of scientific and ethical considerations. All subjects gave written 
informed consent and for AD patients, a relative also signed the consent form. 
Rating Scales 
Dementia severity was rated by trained members of the clinical research team using 
the Global Deterioration Scale (Reisberg et al., 1982) and the Clinical Dementia Rating 
Scale (Hughes et al., 1982). They were also evaluated with the Dementia Mood Assess- 
ment Scale (DMAS) (Sunderland et al., 1988a, 1988b), a 24-item scale in which the first 
17 items were designed to measure mood in dementia (DMAS-17) and the last 7 items 
to measure cognitive and functional impairment. We also used the modified Bunney- 
Hamburg Global Behavioral Rating Scales (Bunney & Hamburg, 1963; Sunderland et al., 
1988a) to rate aspects of behavior and mood, with scores ranging from 0 (no impairment) to 
13-15 (very severe). High inter-rater reliability had been established previously for both 
the DMAS-17 and the Global Rating Scales in a group of AD patients (Sunderland et 
al., 1988a). To rate depression severity in patients diagnosed with major depression, we 
used the Hamilton Depression Scale (Hamilton, 1960) as well as the Bunney-Hamburg 
Global Behavioral Rating Scales. 
CSF Measures 
After an overnight fast, lumbar punctures were performed between 0800h and 0900h 
on subjects in the lateral decubitus position. Subjects were on bed-rest prior to the lumbar 
puncture, except for voiding. The lumbar puncture was usually the last test done during 
a patients's hospitalization, and care was taken to leave enough days between it and 
other tests that were done. The 26th milliliter of collected CSF was immediately frozen 
without preservatives on dry ice and then stored at -70°C for later measurement of SLI. 
The SLI radioimmunoassay (RIA) used '25I-tyrosine-l-somatostatin, rabbit antisomato- 
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statin antiserum (INC-STAR Corp., Stillwater, MN), synthetic cyclic somatostatin stan- 
dards, and charcoal separation, and was performed using procedures described elsewhere 
(Patel et al., 1977). Assay sensitivity is 1 pg/tube, with an EDs0 of 8.6 pg/tube. The 
antisomatostatin antibody used is directed toward the midportion of the tetradecapeptide, 
so it recognizes N-terminal extensions of SRIF-14, such as SRIF-28. SLI for all subjects 
was measured in one of two large assays, and samples from AD, depressed, and normal 
subjects were run in the same assays. All samples were measured in duplicate. The 
intraassay coefficient of variation was about 6%; the interassay coefficient of variation 
for this assay is 12-15%. 
The CSF CRF RIA has been described in detail (Banki et al., 1987; Nemeroff et al., 
1984) and included an ovine CRF antiserum provided by Dr. Wylie Vale (Salk Institute, 
La Jolla, CA). The assay has a sensitivity of 2.5 pg/tube (6.25 pg/ml), an IC50 of 40 pg, 
and recognizes the CRF molecule in the 33-41 amino acid region. All samples were 
measured in a single assay with an intraassay variation of 7.9%. 
Plasma and Urinary Free Cortisol 
Fourteen of the AD and 10 of the depressed patients received a DST, in which 1 mg 
of dexamethasone was ingested at 2300h and blood for cortisol measurement was collected 
at 0800h and 1600h the following day, after which they were stored at -70°C. Duplicate 
samples of serum cortisol were measured using RIA by Hazelton Laboratories, Rockville, 
MD. Within- and between-assay variations were 5.8% and 9.7%, respectively. Subjects 
were considered nonsuppressors if either the 0800h or the 1600h postdexamethasone 
cortisol was > 5 mg/dl. 
The 24-hour urine collections were done by both patient groups under close supervision 
by nursing staff; aliquots were stored at -70°C. Urinary free cortisol (UFC) was measured 
using RIA by Hazleton Laboratories. Assay sensitivity is 0.2 mg/dl, with negligible cross- 
reactivity to other naturally occurring steroids, and coefficient of variation was 4.6%. 
Data Analysis 
Age, CSF SLI, and HPA axis measures were compared between diagnostic groups 
by one-way ANOVA and post hoc Bonferroni t-tests (two-tailed). Pearson's product- 
moment correlations (r) were used to explore relationships between CSF SLI, HPA 
measures, age, duration of illness, dementia severity, and mood. Comparison of CSF 
SLI with respect to gender and age of onset (>65 and &e<65) was made using Student's 
t-test (two-tailed). A Fisher's exact test was used to determine any difference between 
rates of DST nonsuppression between patient groups. Data are presented as the mean 
--- SD. 
RESULTS 
CSF SLI and Demographic and Clinical Variables 
CSF SLI concentrations and DST results for the depressed patients and controls and 
for 34 of the AD patients had been reported previously (Molchan et al., 1990, 1991a). 
Those data are included here as background for the examination of relationships with 
the HPA axis and clinical measures. Means for demographic and clinical variables for 
the patient groups are summarized in Table I. As reported previously (Bissette et al., 
1986; Davis et al., 1988; Molchan et al., 1991; Sunderland et al., 1987), the CSF SLI 
concentration of age-matched controls (62.4 --- 13.3 pg/ml) was significantly higher than 
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TABLE II. BIOLOGICAL DATA FOR ALZHEIMER'S AND MAJOR DEPRESSION PATIENTS 
Measure (mean ± SD) Alzheimer's Depression 
CSF SLI (pg/ml)* 
CSF CRH (pg/ml)* 
Baseline cortisol (/zg/dl) 
Post-dexamethasone plasma cortisol (/zg/dl) 
0800h 
1600h 
% subjects with post-dex cortisol > 5/xg/dl 
Urinary free cortisol (/zg/24 h) 
36.9 --- 15.2 (49) 45.1 -+ 15.5 (18) 
76.7 --- 26.1 (49) 78.6 -+ 24.6 (18) 
15.9 --+ 6.6 (13) 20.1 --- 12.6 (9) 
1.5 --+ 0.7 (14) 7.6 --- 10.5 (10)** 
3.1 --- 2.9 (14) 6.8 -+ 8.0 (9) 
21.4 (3) 60.0 (6)t 
61.2 - 31.3 (23) 92.3 --- 62.6 (16)t 
Number of subjects is given in parentheses. 
*For normal controls CSF SLI = 62.4 ± 13.3 pg/ml (n = 13) and CRF = 87.1 ± 15.8 pg/ml (n = 11). 
**p < .05, tp < .09 difference between groups. 
that of  both patient groups (F[2, 77] = 12.9, p < .001), and the levels between the AD 
and depressed patients did not differ significantly from each other  (Table II). In the 
present  study, age did not correlate with CSF SLI in either patient group, though it did 
within the group of  13 normal controls (r = 0.61, p < .03). No difference in CSF SLI  
concentrat ion was found between genders within any of  the subject groups, though the 
small sample size and inclusion of  only three women in the normal control  group increases 
the possibility of  a false negative conclusion. 
There  were no significant correlations between CSF SLI and measures of  dementia  
severity; r = -0 .06 ,  p < .68, n = 49 for the Clinical Dementia  Rating, and r = -0 .02 ,  
p < .89, n = 49 for the Global Deterioration Scale, nor was there a significant correlation 
between duration of  dementia symptoms and SLI (r = -0 .13 ,  p < .37, n = 49). CSF 
SLI  was not significantly different between AD patients with presenile-onset (age <65) 
(35.3 --- 15.1 pg/ml, N = 26) and senile-onset (39.3 - 16.0 pg/ml, N = 23) of  illness. 
SLI and Mood Measures 
Within the AD group, CSF SLI correlated with the degree of  depression as measured 
by the DMAS (17 item) (r = -0 .40 ,  n = 49, p < .005), but not with the Global Depression 
Score (r = -0 .17 ,  n = 49, p < .23). Of the other  Global Scale measures,  only psychosis  
correlated significantly with CSF SLI  (r = -0 .33 ,  n = 49, p < .02). 
Within the group of  patients with major depression, the Hamilton Depression Scale 
(both 17-item and total) score did not correlate significantly with CSF SLI (r = -0 .41 ,  
N = 18, p < .09, and r = -0 .36 ,  N = 18, p < . 15, respectively); nor did the Global 
Scale scores correlate significantly with CSF SLI concentration. 
HPA Axis Measures 
CSF CRF concentrat ions were not significantly different among subjects groups (F[2, 
77] = 0.80; p < .46) (Table II) (CSF CRF = 87.1 - 15.8 pg/ml, n = 11 normal controls). 
Normal  controls did not participate in the DST or urine collections; the mean measures 
for the patient groups for these tests are summarized in Table II. The depressed patients 
had higher pos tdexamethasone  cortisol concentrat ions than the AD patients, significantly 
for the 0800h measure.  The rate of  DST nonsuppression and mean UFC level also tended 
to be higher within the group of  depressed as compared with the AD patients (p < .09). 
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T A B L E  I I I .  C O R R E L A T I O N S  B E T W E E N  C S F  S L I  A N D  H P A  
AXIS MEASURES 
Measure Alzheimer's Depressed 
CSF CRH 0.49 (49)* 0.47 (16)~t 
Max post-dex plasma cortisol 0.23 (14) 0.22 (10) 
Urinary free cortisol - 0.51 (23)t - 0.54 (16)5" 
The correlation coefficient (r) and number of subjects is given for each correlation. 
*p < .0004, tp < .03, :~p < .07. 
S L I  and HPA Axis Measures 
Table III summarizes correlations between CSF SLI and HPA axis measures for the 
patient groups. CSF CRF and SLI concentrations correlated positively within each group, 
significantly in the AD group and at a trend level in the depressed patients. Within the 
group of normal controls, CSF SLI and CRF did not correlate (r = 0.08, p < .84). 
Postdexamethasone plasma cortisol levels did not correlate with SLI in either patient 
group, and UFC correlated negatively with SLI in both groups (Table III). There was 
no significant difference in CSF SLI between DST suppressors and nonsuppressors in 
either the AD (t = 0.89, d f  = 12, p < .39) or the depressed group (t = 0.31, d f  = 8, p 
< .77). Of the HPA measures, only CRF and UFC correlated significantly within the 
AD group (r -- -0.43, p < .05), although not in the group with major depression (r = 
0.1, p < .71). 
DISCUSSION 
As reported previously, CSF SL! was significantly decreased in the patients with AD 
and major depression as compared with normal controls (Agren & Lundqvist, 1984; Beal 
et al., 1986; Davis et al., 1988; Molchan et al., 1991a; Oram et al., 1981; Rubinow, 1986; 
Soininen et al., 1984; Sunderland et al., 1987). Not previously reported for this patient 
sample, and consistent with most (McDonald & Nemeroff, 1991; Nemeroff et al., 1984; 
Pomara et al., 1989) but not all prior studies (May et al., 1987; Mouradian et al., 1986; 
Suemaru et al., 1991), mean CSF CRF did not differ significantly between AD patients 
and controls. 
In patients with major depression too, no significant difference was found in CRF 
when compared with normals. This is different from the increased CRF concentrations 
reported in most studies of depressed patients (Nemeroff, 1992; Nemeroff et al., 1984). 
Those prior studies included younger patients, and age has been shown to be related to 
other HPA axis abnormalities, such as hypercortisolemia and DST nonsuppression, in 
patient groups (Greden et al., 1986; Sapolsky et al., 1987). Conceivably, the negative 
feedback of this hypercortisolemia could act to lower CRF concentrations, which may 
otherwise have been elevated, as in younger depressed patients. Many of the older 
patients included in our study too, were probably more chronically depressed than 
younger patients included in prior studies. Older patients often have more persistent 
symptoms and may be less likely to recover fully (Blazer, 1989). Such chronic depression 
may lead to greater adrenal gland hypertrophy over time, and increased rates and levels 
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of hypercortisolemia (Amsterdam et al., 1987; Nemeroff et al., 1992). To test this hypothe- 
sis more completely, larger numbers of older subjects need to be studied. 
It should also be noted that the mean CRF concentration for our normal control group 
(87.1 pg/ml) was high compared to values for normals from prior studies (40-60 pg/ml) 
(Banki et al., 1987; France et al., 1988; Nemeroff et al., 1984). Prior studies included 
subjects of lower mean age than those included in our study, and although age has not 
been shown to correlate with CRF concentration (Banki et al., 1987; France et al., 1988), 
further studies should be done on its effects on CSF CRF and other HPA axis measures. 
Relationships between SLI and CRF and UFC have not, to our knowledge, been 
examined in AD patients. Consistent with some prior studies in other patient groups, 
CSF SLI correlated positively with CSF CRF within each of our patient groups (Berrettini 
et al., 1987; Kaye et al., 1988; Rubinow et al., 1987), though in the depressed patients 
at a trend level of statistical significance. UFC correlated negatively with CSF SLI within 
each patient group (Table III), consistent with prior findings of inverse correlations 
between plasma cortisol and CSF SLI (Doran et al., 1986; Kaye et al., 1988; Rubinow, 
1986), including in one study of dementia patients (Serby et al., 1986). Decreased SLI 
may be secondary to increased peripheral cortisol levels, in that SLI secretion has been 
shown to decrease after dexamethasone in vitro (Cote et al., 1986), and CSF SLI levels 
in humans have been shown to decrease after prednisone administration (Wolkowitz et 
al., 1987). Conversely, possibly with decreased SLI concentrations, and therefore a loss 
of inhibitory feedback (Brown et al., 1984; Heisler et al., 1982; Lamberts, 1988; Nicholson 
et al., 1984; Reisine, 1984; Richardson & Schronbrunn, 1981) on CRF and ACTH in 
these pathological states, a hypercortisolemic state may ensue (Doran et al., 1986; Kaye 
et al., 1988; Rubinow, 1986; Wolkowitz et al., 1987). A suprapituitary source of neuroen- 
docrine alterations has also been indicated by CRF stimulation test responses in patients 
with major depression (Gold et al., 1986; Holsboer et al., 1984; Lesch et al., 1988) and 
in one study of patients with AD (Lesch et al., 1990), in that ACTH responses have 
been shown to be blunted as compared to controls, with normal cortisol responses. 
Another indication that the neuroendocrine abnormalities in AD may arise from a 
central source is that hypothalamic neuropathology has been documented in the illness 
(Hirano & Zimmerman, 1962; Ishii, 1966; Saper & German, 1987; Sparks et al., 1988). 
As noted above, decreased hypothalamic somatostatin may allow a disinhibition of the 
HPA axis (Rubinow, 1986). Alternatively, the somatostatinergic and HPA systems may 
be disrupted because of pathology that affects each of them separately, or the HPA 
axis may become disinhibited by an indirect effect of somatostatin via, for example, 
catecholamines, which regulate the HPA axis (Brown et al., 1984; Doran et al., 1986; 
Garcia-Sevilla et al., 1978; Gothert, 1980). Loss of glucocorticoid receptors from another 
central site of pathology in AD, the hippocampus (Coyle et al., 1983; Katzman, 1986), and 
subsequent feedback insensitivity, has also been hypothesized to lead to glucocorticoid 
hypersecretion (Sapolsky et al., 1987). 
The negative correlations between UFC and CRF within the group of AD patients 
may be an indication of a relatively intact feedback mechanism onto CRF, hence CRF 
concentrations were not shown to be elevated as compared with normal controls. There 
was no correlation between CRF and UFC in the depressed patients, possibly because 
the mechanisms of the HPA aberrations in depression differ from that in AD patients. 
Some studies have indicated that a deficient glucocorticoid feedback response may con- 
tribute to the HPA abnormalities in depression (Axelrod & Reisine, 1984; Lesch et al., 
1988; Lowy et al., 1988; Maes et al., 1990). 
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Twenty-four hour collections of UFC have been used as an estimate of circulating 
unbound cortisol secretion (Beisel et al., 1964; Carroll & Mendels, 1976; Eddy et al., 
1973; Lindholm, 1973). The depressed patients in our study had higher UFC levels than 
the AD patients, consistent with the higher mean postdexamethasone plasma cortisol 
concentration in that group and the trend towards a larger number of nonsuppressors. 
Elevated UFC has been reported in patients with major depression in some (Berger et 
al., 1982; Rubin et al., 1987; Stokes et al., 1984) but not all (Vandewalle et al., 1983) 
studies, and in one study of dementia patients (Maeda et al., 1991). 
In AD patients, some (Soininen et al., 1984; Tamminga et al., 1987) but not all studies 
(Beal et al., 1986; Davis et al., 1988; Sunderland et al., 1987) have found significant 
correlations between decreased levels of SLI and dementia severity. Only one previous 
study examined the relationship between SLI level and depression in AD patients and 
as in the present study, no consistent relationship was found (Sunderland et al., 1987). 
Similarly, most though not all (Agren & Lundqvist, 1984) studies of depressed patients 
have not shown a correlation between measures of depressed mood and CSF SLI (Ru- 
binow, 1986; Sunderland et al., 1987). 
Neuroendocrine systems have many overlapping regulatory mechanisms, so it is diffi- 
cult to determine the role of any one substance in the biological abnormalities discussed. 
The positive correlations between CSF SLI and CRF and negative correlations between 
SLI and a peripheral HPA axis measure, UFC, found in the patients in the present and 
prior studies, are indicative of some of these interrelationships. Further studies of clinical 
measures, neuropeptides, and hormones in AD and major depression may encourage 
the development of novel therapeutic approaches and help elucidate the biological mecha- 
nisms of these diseases. 
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